Handbook of Anticancer Pharmacokinetics and Pharmacodynamics

1. Molecular Targets.- 2. Preclinical Screening for New Anticancer Agents.- 3. Natural Product Screening.- 4. Defining the Starting Dose: Should it be mg/kg, mg/m2 or Fixed?.- 5. Phase 0 Trials in Oncology.- 6. Phase I Trials in Oncology - Design and Endpoints.- 7. Quantitative Analytical Methods: Development and Clinical Considerations.- 8. Validation and Control of Bioanalytical Methods.- 9. Anti-Cancer Clinical Pharmacology Overview.- 10. Pharmacokinetic Modeling.- 11. Pharmacometrics.- 12. Pharmacodynamic Modeling.- 13. Protein Binding.- 14. Metabolism (Non-CyP Enzymes).- 15. Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms.- 16. Cytochrome P450.- 17. Polymorphisms in Genes of Drug Targets and Metabolism.- 18. DNA Repair: ERCC1, Nucleotide Excision Repair, and Platinum Resistance.- 19. Drug Interactions.- 20. ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition.- 21. Solute carriers.- 22. High Throughput Platforms in Drug Metabolism and Transport Pharmacogenetics.- 23. Intrathecal Administration.- 24. Microdialysis.- 25. Regional Drug Delivery for Inoperable Pulmonary Malignancies.- 26. Blood-Brain-Barrier & CNS Malignancy.- 27. Radiation and Altering Clinical Pharmacology.- 28. Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment.- 29. Recombinant Immunotoxins.- 30. Monoclonal Antibodies.- 31. Clinical Pharmacology in Pediatrics.- 32. Clinical Pharmacology in the Elderly.- 33. Organ Dysfunction Trials: Background, Historical Barriers, Progress in Overcoming Barriers and Suggestions for Future Trials.- 34. Drug Formulations: How this Affects Anticancer Drug Pharmacokinetics and Pharmacodynamics.- 35. Nanotechnology in Cancer.- 36. Imaging in Drug Development.- 37. Exposure-Response Relationship of Anticancer Agents: Application in Drug Development and Drug Label.- 38. The Role of Phase III Trials in Modern Drug Development.- 39. Clinical Trial Designs for Approval of New AnticancerAgents.- 40.

Dr. Michelle Rudek received her BS in Pharmacy from the University of Pittsburgh and her dual Pharm.D., Ph.D. from Virginia Commonwealth University in a joint clinical pharmacology/oncology program with the National Cancer Institute. Dr. Rudek joined Johns Hopkins University in 2001 and is currently an Associate Professor of Oncology and Director of the Analytical Pharmacology Core Laboratory. Her research program is focused on clinical pharmacology with a focus on early phase drug development and special populations including AIDS malignancy and organ dysfunction.

Dr. Cindy H. Chau received her BS in Molecular, Cell, and Developmental Biology from UCLA and her Pharm.D. and Ph.D. (in Molecular Pharmacology and Toxicology) dual degrees from the University of Southern California School of Pharmacy as a National Institutes of Health (NIH) predoctoral fellow. She was the recipient of the NIH National Research Service Award. Dr. Chau completed a postdoctoral fellowship at the NIH, joining the National Cancer Institute in 2004 and is currently a research scientist within the Medical Oncology Branch, Center for Cancer Research.

Dr. William Douglas Figg received his B.S. (Hon) from Georgetown College, his B.S. in Pharmacy from Samford University and his Pharm.D. from Auburn University. He completed his clinical pharmacy internship at the University of Alabama at Birmingham Hospital and his fellowship in drug development at the University of North Carolina-Chapel Hill. Dr. Figg also received an M.B.A. degree from a combined program at Columbia University and London Business School. He joined the Medical Oncology Branch, National Cancer Institute, National Institutes of Health in 1992. He has patented more than 80 new anticancer agents and four pharmacogenetic tests.

Dr. Howard McLeod is Fred Eshelman Distinguished Professor and Director, UNC Institute for Pharmacogenomics and Individualized Therapy,University of North

"...an invaluable overview of the experimental and clinical processes that lead to anticancer drugs, creating a single indispensable reference that covers all the steps from the identification of cancer-specific targets to phase III clinical trials." - Tumori